CDF access to venetoclax for English patients

5 October 2017

Venclyxto (venetoclax) is backed by compelling data in chronic lymphocytic leukemia (CLL) but in order to reach English patients, it has needed the pathway provided by the Cancer Drugs Fund (CDF) .

The oral B-cell lymphoma-2 inhibitor, which is being marketed outside the USA by US drugmaker AbbVie (NYSE: ABBV), has been recommended for use by National Health Service (NHS) for adults with CLL in the absence of 17p deletion or TP53 mutation who have failed both chemo immunotherapy and a B-cell receptor (BCR) inhibitor. It has also been recommended for the treatment of adult CLL patients in the presence of 17p deletion or TP53 mutation who are either unsuitable for or have failed a BCR inhibitor.

"We are hopeful that this will ultimately translate into longer-term routine prescribing on the NHS"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK